ACCCBUZZ BLOG

March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.

While precision medicine in cancer care is becoming more widespread, its rapid evolution in oncology requires ongoing discussion. ACCC’s podcast, CANCER BUZZ, features lively expert discussions about emergent issues in cancer care. Here we highlight some of those podcasts.

ACCC has launched Transforming Complex to Clear—a precision medicine campaign that has developed a range of tools and resources to help bring clarity to complex patient care decisions. Designed for multidisciplinary cancer teams, learn more about how these resources can enable clinicians to make educated and confident decisions.

In launching its new campaign, Transforming Complex To Clear, ACCC brought together expert panelists to discuss effective practices and offer tips to address current barriers to biomarker testing in the community setting.

Liquid biopsy, a genetic test that can eliminate some of the most serious potential drawbacks of traditional tissue biopsy, is gaining more traction in cancer care. But there remain significant barriers to its widespread use.

To help address the ongoing prevalence of colorectal cancer, ACCC is inviting its members to submit proposals for quality improvement initiatives in treating metastatic forms of this cancer.

Led by the Prevent Cancer Foundation, ACCC has joined more than 300 organizations in signing a letter urging the passage of the MCED Screening Coverage Act, which will help cancer care providers be able to use the latest testing technologies to improve quality of life and better patient outcomes.

Montana is one of the most rural states in the U.S., with nearly half of its population living in rural regions. Accordingly, accessing healthcare services can be difficult for Montana’s citizens, and gaining access to clinical trials is particularly challenging.

Recent advances in immuno-oncology (IO) therapies have led to rapid, effective treatments for subsets of patients with cancers that have proven resistant to conventional treatments.

Growing knowledge of NSCLC subtypes and molecular biomarkers for this disease has led to changes in how NSCLC is diagnosed and staged.

In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.